Condition: Hormone-receptor-positive Breast Cancer · HER2-negative Breast Cancer · Metastatic Breast Cancer · Sponsor: BeOne Medicines
This is a dose escalation and dose expansion study to assess the safety and tolerability of BGB-21447 (a B-cell leukemia/lymphoma 2 inhibitor, Bcl-2i) in combination with fulvestrant, with or without BGB-43395 (cyclin-dependent kinase 4 inhibitor, CDK4i), in adults with HR+/HER2- metastatic breast cancer.
This description comes directly from the study's public registry record.
Study Director · 1.877.828.5568 · clinicaltrials@beonemed.com
Always discuss trial participation with your own doctor first.
| University of Iowa Hospitals and Clinics | Iowa City, Iowa, United States | Recruiting |
| Md Anderson Cancer Center | Houston, Texas, United States | Recruiting |
| Fred Hutchinson Cancer Research Center | Seattle, Washington, United States | Recruiting |
| Saint Vincents Hospital Sydney | Darlinghurst, New South Wales, Australia | Recruiting |
| Calvary Mater Newcastle | Waratah, New South Wales, Australia | Recruiting |
| Sunshine Coast University Private Hospital | Birtinya, Queensland, Australia | Recruiting |
| Peter Maccallum Cancer Centre | Melbourne, Victoria, Australia | Recruiting |
| Western Health Sunshine Hospital | St Albans, Victoria, Australia | Recruiting |
| Linear Clinical Research | Nedlands, Western Australia, Australia | Recruiting |
| Sun Yat Sen Memorial Hospital, Sun Yat Sen University (South) | Guangzhou, Guangdong, China | Recruiting |
| The First Affiliated Hospital of Zhengzhou University | Zhengzhou, Henan, China | Recruiting |
| Fudan University Shanghai Cancer Centerpudong | Shanghai, Shanghai Municipality, China | Recruiting |
+ 2 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06756932